Index

[Note to users: Acronyms are used here as main entries where considered to be more familiar terms.]

AAP (American Academy of Pediatrics) 174, 175
abdominal pain see pelvic/abdominal pain
abnormal uterine bleeding (AUB) 275–80
abortion 105–6, 109, 190
abscesses 55, 64–8, 256, 258, 364
abstract thought 86, 114, 115
abuse see sexual abuse
ACA (Affordable Care Act) 112
accidental trauma 19, 72–5
acetaminophen 353, 354
Acien’s classification 330
ACIP (Advisory Committee on Immunization Practices) schedule 123
acne
abnormal uterine bleeding 276
amenorrhea 272
COCs therapy 211, 386
dysmenorrhea 326
endometriosis 354
normal puberty 85
polycystic ovary syndrome 127, 167, 356, 357, 358, 359
prepubertal girls 88, 90
ACOG (American College of Obstetricians and Gynecologists)
adolescent girls’ initial visit 99
cervical cancer screening 174, 176
congenital uterine anomalies 336
DMPA recommendations 228
premenstrual dysphoric disorder 281
ACTS (Advice–Consent–Test–Support) 316
acyclovir 295, 296
adenocarcinoma
cervix 252
vagina 252
vulva 61

adhesions, labial 29–32
adnexal masses 255, 389
adnexal torsion 23, 24, 255, 264, 338, 339, 343, 344, 389
adoption, minors’ consent 105–6
adrenal glands 81, 271, 357
adrenarche 80, 81, 87, 88, 90
agenesis, vaginal 333–6
alcohol abuse 146–50
allodynia, cutaneous 267
alopecia 235
ambiguous genitalia 6–12
amenorrhea 139, 140, 141, 166, 269–74
Amsel’s criteria 289, 290
androgen insensitivity syndrome (AIS) 270, 335
androgen-secreting tumors 235, 236
androgens, hirsutism 234–40
anemias 200, 298–9
anogenital signs/symptoms 39, 377
anorexia nervosa 131–7
anovulation 167
antenatal ovarian mass detection 22–3
anti-Müllerian hormone (AMH) 366
antifibrinolytics 278
antifungal drugs 287–8, 292, 313
antiretroviral (ARV) therapy 201, 317
antiviral treatments 201, 295, 317
aphthosis, vulvar 57–9
appendicitis 258, 264
arcuate uterus 331, 332, 333
ARSHEP (Adolescent Reproductive and Sexual Health Education Project) 187
ASRM (American Society of Reproductive Medicine) classification system 330, 332
asymmetric breasts 241
asymmetric uterine anomalies 331–3
athletes 138–41
azithromycin 320, 321
azole drugs 287–8, 292, 313
bacterial vaginosis (BV) 249, 250, 251, 289–92
barrier contraception 197, 200, 205–9, 291, 305, 317
Bartholin’s gland abscess 55, 65–7
benign masses 242, 243, 343, 348
benzathine penicillin 318, 320
betamethasone 31, 32, 59
bicornuate uterus 331, 332, 333
bisexuality 154–7
bleeding
see also menarche; menstruation
abnormal uterine (AUB) 275–80
hormone use for one year 386
irregular 171–2, 214
pelvic masses 256, 257
prepubertal girls 18–21
straddle injuries 73–4
blood count 123, 262, 340
blood pressure 120, 122, 124, 128, 202
BMI (body mass index) 85, 120, 124, 125, 126, 127
bone health 172
bone mineral density (BMD) 133, 135, 136, 139, 220, 228
botulinum toxin 268
breasts 241–8
athletes 138
concerns 241–5
development 241, 242, 381
see also thelarche
discharge 246–8
examinations 120
nipples 138, 244, 246–8
tenderness 214
bulimia nervosa 131–7
CAH (congenital adrenal hyperplasia) 88, 271
CAIS (complete androgen insensitivity syndrome) 334, 335, 336
calcium intake 139, 354
Calymmatobacterium granulomatis 320
cancer see malignancy
candidal infections
Candida glabrata 287, 288
vaginal discharge 249, 250, 251
vulvar itching 53–4
vulvovaginitis 36, 285–8
cardiocascular disease 101, 202
caregivers see parental/caregiver discussions
CAUV (congenital absence of the uterus and vagina) 333–6
CDC (Centers for Disease Control and Prevention) 120, 128, 130, 133, 142, 143, 309
cefoxitin 363, 364
ceftriaxone 16, 309, 310, 364
central precocious puberty 21, 87, 88, 89
central sensitization 266
cephalosporin 309–10, 364
cervical anomalies 333, 334
cervical cancer
cytology screening 174, 176, 180–2
HIV human immunodeficiency virus 316
HPV human papilloma virus 297, 298, 299, 301
cervical intraepithelial neoplasia (CIN) 180, 181, 182, 298
cervical loop electrosurgical excision procedures (LEEP) 181
cervicitis 250–2
CHCs/COCs (combined hormonal/oral contraceptives) 210–21
acute abnormal uterine bleeding 278
diabetes 202, 203, 204
dysmenorrhea 327, 328
endometriosis 351, 354
medical illness 200, 201, 202, 203, 386
menstrual suppression 169, 171, 172
noncontraceptive benefits 211, 386
ovarian cyst prevention 257
polycystic ovary syndrome 358
switching to/from 215, 386
chemotherapy 272, 350
see also minors; prepubertal girls
Children’s Health Insurance Program 112
Chlamydia trachomatis 302–6
cervicitis 250–1
 intrauterine devices 224
lymphogranulomavenerum 321
pelvic inflammatory disease 361, 362, 363, 364
prepubertal vaginal discharge/odor 16
screening 181, 183, 184, 185
sexual abuse in young children 41
tubo-ovarian abscess 258
chromosomal disorders 92, 94, 270, 271–2, 367–8
chronic abnormal uterine bleeding 279–80
chronic pelvic/abdominal pain 260–3, 388
cimetidine 248, 322
ciprofl oxacin 321
clindamycin 68, 292, 363
clobetasol ointment 70
clue cells 290, 291
cold sores 293, 294
colposcopy 299
complete blood count (CBC) 123, 262, 340
complex ovarian cysts 23, 24
congenital absence of the uterus and vagina 333–6
concrete thinking 114, 115
INDEX

condoms 205, 206, 207, 208
bacterial vaginosis 291
care of 207
chlamydial infection 305
contraception in medical illness 197
HIV 200, 317
condylomas, vulvar 54, 55
confidentiality 99, 102, 103–7
barriers to 104–6
chlamydial infection 303
exceptions 104
federal/state laws 105–6, 110–11
insurance claims handling 112
minors’ consent laws 105–6
sexual history-taking 382
STD screening 107, 183
congenital anomalies
absence of the uterus and vagina (CAUV) 333–6
adrenal hyperplasia (CAH) 88, 271
classification systems 332, 333, 336
hymen 45–7
MRKH syndrome 270, 333–6
Müllerian 330–8, 366–70
consent requirements 105, 108–13, 159, 316
constipation 261
contact dermatitis, vulvar 54
contraception 205–33
see also CHCs/COCs (combined hormonal/oral contraceptives); IUDs (intrauterine devices)
barrier methods 197, 200, 205–9, 291, 305, 317
counseling 192–204
developmental delay 160–2
DMPA 226–8, 229
emergency 230–3
failure 188–9, 205, 207, 209
funding programs 109–10, 111
implantable 201, 202, 203, 215, 228–9, 280, 386
injectable 226–8, 229
Lea’s shield 206, 207, 208
long-acting reversible 197
medical illness 197–204
menstrual suppression 169–73
method switching 215, 386
minors’ consent laws 105–6
obese patients 127
progestin-only 215, 226, 228–9
unintended pregnancy 383–4
copper intrauterine devices 222, 223, 225, 231
corpus luteum 342, 344, 345
cyst 255, 256, 257, 339, 342, 344
counseling 187–204
see also parent/caregiver discussions
contraception 192–6
medical illness 197–204
unintended pregnancy 187–91
CRAFFT screening tool 147, 148
crèmbriform hymen 45, 46, 47–8
CT see imaging
culture microorganisms
acute vulvar ulcerations 58
candidal vulvovaginal 286, 287, 288
cervicitis 251
prepubertal vulvovaginitis 33, 34, 35
STIs screening 184–5, 309, 313
tubo-ovarian abscess 258
cutaneous allodynia 267
cyproterone acetate 239, 240
cystadenoma 21, 255, 343, 344, 345
cysts
corpus luteum 342, 344, 345
dermoid 26–7, 348
ovarian 23, 24, 28, 89, 342–7, 355–60
unilocular 388
vulvar 60–3
cytology, cervical 174, 176, 180–2, 184, 316
date rape 371–5
DECISION model 187–90
delayed puberty 91–6
depilation, hirsutism 238
depression 203, 281–4, 356
dermatologic conditions see skin conditions
dermoid cysts/tumors 26–7, 348
development
adolescent stages 381
breasts 381
abnormalities 241, 242
developmental delay (DD) 158–62
male/female genitalia 7–8
reproductive tract 256, 257–8
gonadal dysgenesis 366–70
ovarian 22, 348–50
sexuality 114–18
dEXA (bone densitometry) scans 135, 139
DHEA (dehydroepiandrosterone) 81, 91
DHEAS (dehydroepiandrosterone sulfate) 81, 88, 91, 357
diabetes 128, 202–3, 356
Diagnostic and Statistical Manual of Mental Disorders
criteria 131, 132, 281, 282
diaphragm contraception 206, 207, 208
diarrhea
abdominal/pelvic pain 261, 262, 264
dysmenorrhea 326
pelvic masses 258
prepubertal girls 16, 58
sexually-transmitted infections 16
vaginal discharge/odor 15
didelphys uterus 331, 332
diphtheria toxoid 142
directive contraception counseling 194–6
dysgerminomas of the ovary 348

dysmenorrhea 325–9, 332, 351

dyspareunia due to endometriosis 351

dysuria, vulvar pain 33

early adolescence 114, 115, 120, 192–3, 381

eating disorders 131–7, 139–41

ectopic pregnancy 256–7, 280, 339–41

educational resources 104, 156, 190, 305, 390–1

efavirenz 317

eflornithine 239

electrolysis for hirsutism 238

ELISA (enzyme-linked immunosorbent assay) 185, 186

emancipation status 109

emergency contraception 230–3

emotional well-being 151–3, 203, 296, 373–5, 388

endocrine disorders 20, 276

endometrial hyperplasia 356

dysmenorrhea 326, 351–4

enteric pathogens 15

Enterobius vermicularis 36

epidermodysplasia verruciformis 298

epidermoid inclusion cyst 60–1

erythromycin 321

estrogens

abnormal uterine bleeding 278–79

combined oral contraceptives 210

delayed puberty 95

prepubertal labial adhesions 29, 30, 31, 32

prepubertal vaginal bleeding 20

replacement therapy 370

systemic lupus erythematosus 200

ethinyl estradiol 231, 239

eugonadal amenorrhea 269–71

eugonadotropic eugonadism 94

examination positions 40–1

examination under anesthesia (EUA) 18

exercise 138–41, 328, 358

exercise-associated amenorrhea (EAA) 139, 140, 141

expedited partner therapy (EPT) 304

Explanations of Benefits (EOBs) 112

external genitalia differentiation 8

failure of contraception 205, 207, 209


famcyclovir 295

family history 100–1, 275

family planning 109–10

funding programs 109–10, 111

see also contraception

family violence 156

Fanconi anemia 298–9

FDA (Food & Drug Administration) 164

female genital mutilation (FGM) 76–9

female genitalia differentiation 7–8

female-controlled barrier contraception 206, 207–9

drug–drug interactions 171, 220, 317

DSM-IV-TR Diagnostic and Statistical Manual criteria 131, 132, 281, 282

dysfunctional uterine bleeding 275–80

drug treatments

acute abnormal uterine bleeding 278

antiretroviral therapy 201

bacterial vaginosis 292

candidal vulvovaginal infections 287–8

dysmenorrhea 328

ectopic pregnancy 340–1

endometriosis 353, 354

galactorrhoea, causation 248

genital herpes 295

gonorrhea 309–10

hirsutism 239

HIV infection 317

HPV infection 300, 301

lymphogranuloma venereum 321

menstrual suppression 169–73

molluscum contagiosum 322

myofascial (musculoskeletal) pain 267–8

obesity 129

pelvic inflammatory disease 363, 364

polycystic ovary syndrome 358–9

premenstrual syndrome/dysphoric disorder 283, 284

pubic lice 323

syphilis 318, 319, 320

drug–drug interactions 171, 220, 317

DSM-IV-TR Diagnostic and Statistical Manual criteria 131, 132, 281, 282

dysfunctional uterine bleeding 275–80

discharge

nipples 244, 246–8

vaginal 249–53

bacterial vaginosis 249, 250, 251, 289–92

candidal 36, 53–4, 249, 250, 251, 285–8

chlamydia 302–6

prepubertal girls 14–17, 50–1

Trichomonas vaginalis 312–14

disclosure of information 38, 104, 111

disorders of sexual development (DSD)

ambiguous genitalia 6–12

breasts 241, 242

genital abnormalities 6–12, 252

gonadal dysgenesis 366–7

obstructive anomalies 257–8

DMPA (depot medroxyprogesterone acetate) 226–8, 229

anemias 200

diabetes 202, 203

menstrual suppression 169, 170, 171, 172

DNA detection tests

cervicitis 251

chlamydial infection 304

gonorrhea 309, 310

human immunodeficiency virus 315

human papilloma virus 299

donovanoatisis (granuloma inguinale) 320–1

donut sign 91

doxycycline 320, 363, 364

drug treatments

acute abnormal uterine bleeding 278

antiretroviral therapy 201

bacterial vaginosis 292

candidal vulvovaginal infections 287–8

dysmenorrhea 328

ectopic pregnancy 340–1

endometriosis 353, 354

galactorrhea, causation 248

genital herpes 295

gonorrhea 309–10

hirsutism 239

HIV infection 317

HPV infection 300, 301

lymphogranuloma venereum 321

menstrual suppression 169–73

molluscum contagiosum 322

myofascial (musculoskeletal) pain 267–8

obesity 129

pelvic inflammatory disease 363, 364

polycystic ovary syndrome 358–9

premenstrual syndrome/dysphoric disorder 283, 284

pubic lice 323

syphilis 318, 319, 320

drug–drug interactions 171, 220, 317

DSM-IV-TR Diagnostic and Statistical Manual criteria 131, 132, 281, 282

dysfunctional uterine bleeding 275–80
female-pattern baldness 235
FemCap 206, 208–9
Ferriman–Gallwey hirsutism scoring system 234, 235
fetal ovarian masses 22–3
fibroadenoma of breast 243
fibroepithelial polyps 54, 55, 61
finasteride 239, 240
fistulae, vaginal discharge 252–3
flora, normal vulvar 64
flutamide 239
follicles, ovarian cysts 342
follicular cysts 24, 25
folliculitis, vulvar 61–2
follow-up visits 213–14, 363–4
foreign bodies 15, 19, 34–5, 252
FORWARD study (2007) 76
FSH (follicle-stimulating hormone) 80, 81, 95, 273, 357
functional ovarian cysts 342, 343

galactorrhea 246–8, 272
Gardnerella vaginalis 249, 289
gastroenterologic pain causes 261, 264, 388
gastrointestinal conditions 256, 258–9
gender assignment 369
gender neutral terminology 9, 12
gender roles 154–7
general examinations prepubertal 3, 4
genetic factors/diseases
  lichen sclerosus 69
  Müllerian anomalies 330
  polycystic ovary syndrome 355–60
  premenstrual dysphoric disorder 281
  sex determination/differentiation 366–7
  Turner syndrome 92, 94, 271–2, 367–8
genital herpes 293–6
genital syphilitic ulcers 319, 320
genital warts 297, 298, 299, 300, 301
genitourinary examinations 120, 123
germ cell tumors, ovarian 348–50
granular cell tumors, vulvar 62
giant fibroadenomas, breast 243
GLBTQ (gay, lesbian, bisexual, transgender, and questioning) youth 115, 117
glycemic tolerance test 358
gonadal dysgenesis 271, 366–70
gonadarche, normal 80
gonadotropin-releasing hormone (GnRH) agonists 170, 239
  combined oral contraceptives 210
  delayed puberty 93, 94, 95
dysmenorrhea 329
endometriosis 353
female athletes 140
normal puberty 80, 81
precocious puberty 89
gonorrhea 224, 307–11
Gram staining 309
granular cell tumors, vulvar 62
granuloma inguinale 320–1
growth 85, 120, 124, 158–62
  see also development
growth hormone (GH) therapy 367
gynecologic examination 174–82—see also genitourinary examination, physical examination
gynecologic pain 260–8
Haemophilus influenzae 36, 37
hair growth 234–40, 238
  pubarche 20–1, 87, 88, 89, 91
hCG (human chorionic gonadotropin) 123, 340, 341, 345
hearing tests 123
HEEADSSS (Adolescent Psychosocial History and Risk Assessment) also HEADSS 102
hemangiomas, vulvar 62
hematocolpos 46
hematomas, vulvar 74
hepatitis B surface antigen 184
hernias, inguinal 62
hidradenitis suppurativa 67–8, 111, 112
high-grade squamous intraepithelial lesions (HSIL) 181
HIPAA (Health Insurance Portability and Accountability Act) 107, 110, 111, 112
hirsutism 234–40, 273
history-taking 380
amenorrhea 272–3
candidal vulvovaginal infections 286
chronic pelvic/abdominal pain 261–2
endometriosis 352
gonorrhea 308
HIV (human immunodeficiency virus) 315–17
  associated conditions 316
cervical cytology screening 180, 182
  confidential services availability 105
  contraceptive counseling 200–1
herpes simplex virus type 2 294
  screening 184, 185, 186
  sexual assault 372
  syphilis co-infection 318
  Trichomonas vaginalis 312, 313
homosexuality 117, 154–7
hormonal treatments 169–73, 210–16, 230–2, 238
  see also CHCs/COCs (combined hormonal/oral contraceptives); individual hormones
hormone imbalance 276, 277
hospitalization 136, 363
HPV (human papilloma virus) 297–301, 316
  prepubertal vaginal discharge/odor 16
  vaccine 142–3, 144, 176, 180, 182
  vulvar signs/symptoms 52
HSV (herpes simplex virus)
  genital herpes 293–6
  prepubertal vaginal discharge/odor 16
  prepubertal vulvar pain 53
  types 1/2 distinction 293, 294
  vulvar ulcers 57
17-hydroxyprogesterone 9, 10, 11, 88, 357
hygiene
  menstrual 158, 159, 160
  perineal, prepubertal vulvovaginitis 35
  prepubertal labial adhesions 30
  prepubertal vulvovaginitis 33, 35
  vulvar 51, 70–1
  hymen 45–8, 257, 270, 372
  acquired anomalies 47
hyperandrogenism 234, 235, 237, 239, 240, 355–60
hypergonadal hypogonadism 270, 271–2
hypergonadotropic hypogonadism 92, 93, 94
hyperlipidemia 128
hypertension 128, 202
hypogonadal hypogonadism 270, 272
hypogonadotrophic hypogonadism 93–4
hypogonadotropism 94, 95
hypothalamic suppression 272
hypothalamic–pituitary–ovarian (HPO) axis 80–1, 85, 91, 272
hypothyroidism 272
imaging
  abnormal uterine bleeding 276
  amenorrhea 272, 273
  breast discharge 248
  delayed puberty 93, 95
  eating disorders 133
  endometriosis 352
  fistula 253
  obstructive anomaly 257–8
  ovarian mass 24, 25
  pelvic inflammatory disease 363
  pelvic mass 254, 343
  pelvic pain 262–3
    acute 264
    dysmenorrhea 326
  Turner syndrome 368
  uterine anomalies 252, 254, 331, 333, 334, 335, 337
  vulvar mass 60
  see also ultrasound
immunizations 123, 142–5, 180, 182
impetigo 61
implantable contraception 201, 202, 203, 215, 228–9, 280, 386
incision and drainage 64, 65
incomplete fenestration, hymen 45, 46–8
indirect (nontreponemal) syphilis test 318
infants 3–5, 6–12
infectious vulvar folliculitis 61–2
infertility 356
influenza vaccine 143
information disclosure 38, 104, 111
  see also confidentiality
information resources 104, 156, 190, 305, 390–1
initial assessments 3–5, 99–102, 119–20, 121, 211–13
injectable contraception 226–8, 229
injury see trauma/injury
insulin resistance 202–3, 355–60
insulin-like growth factor (IGF) 355
insulin-sensitizing medications 359
insurance, medical 107, 110, 111–12
interview methods 101, 193
intraductal papillomas 244
irregular bleeding 171–2, 214
itching, vulvar 50, 53–4
IUDs (intrauterine devices) 222–5
  contraception in medical illness 197, 198
  insertion 223–5
  menstrual suppression 169, 170, 171
  switching to/from COCs 215, 387
Jarisch–Herxheimer reaction 319–20
juvenile papillomatosis 243
kisspeptin 81, 94
Klebsiella granulomatis 320
knee–chest exam position 41
labial adhesions 29–32
lactation, galactorrhea 246–8
Lactobacillus spp. 249, 289, 291
laparoscopy 263, 264, 352
laser hair removal treatment 238
late adolescence stage 114, 115, 120, 381
lateral decubitus position 41
Lea’s shield 206, 207, 208
LEEP–loop electrosurgical excision procedures 181
legal aspects 78, 104–7, 108–13
leiomyomas 62, 258
leptin 81
lesbian, gay, bisexual, transgender, and questioning (LGBTQ) youth 154–7
leuprolide acetate 171, 239
LH (luteinizing hormone)
  amenorrhea 273
  delayed puberty 95
  normal puberty 80, 81
  polycystic ovary syndrome 355, 357
  premature thelarche 88, 89
lice, pubic 322–3
lichen sclerosus, vulvar 50, 69–71
lindane shampoo 323
lipid screening 123
lipoma, vulvar 62
LNG (levonorgestrel) 230, 231, 232, 233
LNG-IUD (levonorgestrel intrauterine device) 222, 223, 225
diabetes 202, 203
dysmenorrhea 325–9
endometriosis 333, 354
menstrual suppression 169, 170, 171
long-acting reversible contraceptives 197
long-term PID complications 364
longitudinal vaginal septum 337–8
low-grade squamous intraepithelial lesions (LSIL) 181, 182, 298
lymphangioma, vulvar 62
lymphogranuloma venereum (LGV) 321
McCune–Albright syndrome 20–1, 24, 89
magnetic resonance imaging (MRI) 257–8, 326
male genitalia differentiation 7–8
male pattern hair 234–40
malignancy
adenal masses 389
breasts 243–4
cervical cancer 298, 299, 301
screening 180–2, 184
family history 101
malignant ovarian germ cell tumors 349, 350
ovarian masses 26, 255, 256, 343–4, 388
vaginal discharge 252
vulvar 62
malignant ovarian germ cell tumors (MOGCTs) 348, 349, 350
mammary duct ectasia 244
mammography 242
marsupialization, Bartholin’s gland 67
mastalgia 243
mature cystic teratomas (MCTs) 349, 350
Maudsley family-based therapy 136
median body weight (MBW) 136
Medicaid funding program 110, 111, 112
Medical Eligibility Criteria 198, 200, 210, 211, 229, 232
medical illness 197–204, 211, 377
menarche
amenorrhea 269
delayed 91, 92, 158–62
normal 80, 81, 82, 166
premature 89–90
meningococcal vaccine 142, 143
menstrual cups 164
menstruation
abnormal uterine bleeding 275–80
amenorrhea 269–74
developmental delay 160, 161
dysfunctional bleeding 275–80
dysmenorrhea 325–9
history 120
menorrhagia 276
myofascial (musculoskeletal) pain 267
normal 163–73, 381
obese patients 127
oligomenorrhea 355–60
oral contraception 214
pads 163
premenstrual syndrome 281–4
suppression 169–73
tampons 47, 48, 163, 164, 338
mental health
chronic pelvic pain 261, 388
genital herpes 296
LGBTQ healthcare 154–6
mood disorders 281–4
premenstrual syndrome/dysphoric disorder 281–4
screening 387
sexual assault 373–4
mesenchymal tumors, vulvar 61
metabolic syndrome 336
metastatic breast disease 243–4
metformin 240, 271, 356, 359
methotrexate 68, 340–1
metronidazole 313–14
microperforate hymen 45, 46, 47
middle adolescence stage 114, 115, 120, 193–4, 380
migraine 201–2
miniforms 165
minors 104–7, 108, 109, 110
consent laws 107
missed contraceptive pills 213
mixed echogenic adenal masses 389
mixed gonadal dysgenesis 369
molecular genetics 366–7
molluscum contagiosum 52, 299, 321–2
Montgomery’s tubules or tubercles 243, 246
mood disorders 281–4
MRI see imaging
MRKH (Mayer–Rokitansky–Küster–Hauser) syndrome 270, 333–6
MRSA (methicillin-resistant Staphylococcus aureus) 64, 65
Müllerian anomalies 270, 330–8, 366–70
Müllerian inhibiting substance (MIS) 269, 270, 271, 335
multidisciplinary teams 9, 11, 12, 369, 371
multiple vaccination 144–5
musculoskeletal athletics injuries 138–9
musculoskeletal causes of pain 261, 262, 388
musculoskeletal pain syndrome 266–8
NAATs (nucleic acid amplification tests) 185, 251, 304, 309, 310, 315
National Institute on Alcoholism and Alcohol Abuse 148
INDEX

nausea 213
see also vomiting
necrotizing fasciitis, vulvar 66
Neisseria gonorrhoeae 361, 362, 363, 364
Bartholin’s gland abscess 65
cervicitis 251–2
prepubertal vaginal discharge/odor 16
screening 181, 183, 184, 185
sexual abuse in young children 41
tubo-ovarian abscess 258
neonates 6–12, 23–4
neurosphisis 319
NextChoice® 230, 232, 233
NHANES (National Health and Nutrition Examination Survey) 125
nipples 138, 244, 246–8
nonclassic congenital adrenal hyperplasia (NCAH) 357
nondirective contraceptive counseling 194–6
nonspecific vulvovaginitis 15, 34
normal puberty 80–6
NSAIDs (nonsteroidal antiinflammatory drugs) 278, 327, 328, 329, 332, 333, 334
nutrition 125, 139–41
obesity 125–30, 355, 356, 357
dietary interventions 129
obstructive uterine anomalies 256, 257–8, 337
office confidentiality 104, 107
oligomenorrhoea 355–60
oral contraception 210–16, 238, 261, 283
see also CHCs/COCs (combined hormonal/oral contraceptives)
orlistat 129
orthopedic issues 138–9, 261, 262, 266–8, 388
osteoporosis 139
ovarian cysts 89, 342–7
adolescent 342–7
COC prevention method 257
complex/simple 23, 24, 28
corpus luteum 255, 256, 257, 339, 342, 344
cystadenoma 21, 255, 343, 344, 345
dermoid 26–7, 348
fetal 22–3
follicular 21, 22, 24, 255, 342, 344
functional 23, 25, 28, 254, 342, 347
vaginal bleeding 21
neonatal 23–4, 344
precocious puberty 89
prepubertal 24–8
polycystic ovary syndrome 127, 167, 234–5, 271, 355–60
and torsion 24, 25, 28, 343, 344
see also ovarian tumors
ovarian mass see ovarian cysts, ovarian tumors
ovarian torsion 24–5, 253–6, 264, 338, 339, 343, 344, 389
prepubertal 25, 28
ovarian tumors
antenatal detection 22–3
childhood detection 24
dermoid 26–7
functional cyst 342, 343
germ cell 348–50
malignancy 26, 255, 256, 343–4, 348, 349, 350, 388
masses 255–6, 388
neonatal detection 23–4
prepubertal 22–8
ovaries 342–50
amenorrhoea 269–74
overweight 125–30, 355, 356, 357
padded panties 164
pain
acute pelvic 263–5, 344–7
chronic pelvic 260–3, 388
dysmenorrhea 323–9
ectopic pregnancy 256–7, 280, 339–41
endometriosis 351–4
gynecologic 260–8
IUD insertion 224
ovarian cysts 342–3, 344–7
ovarian germ cell tumors 348–50
ovarian/adnexal torsion 25, 28, 255, 389
vulvar 53, 55–6
Pap test/smear 180–2, 184, 316
papillomas, breast intraductal 244
parental consent, adolescents 108
parental monitoring 116, 117
parental/caregiver discussions
ambiguous genitalia 11–12
confidentiality of minors 104
delayed puberty 95
eating disorders 137
emotional well-being screening 152
female genital mutilation 79
granuloma inguinale 320
initial assessment 100, 101, 102, 104
legal aspects 108, 111, 112
sexual assault 373–4
sexuality 118
uterine abnormalities 332–3
vulvar signs/symptoms 49
patient information
see also parental/caregiver discussions
LGBTQ healthcare 156
menstrual suppression 172
obesity treatment 130
prepubertal labial adhesions 30
prepubertal vulvovaginitis 36
resources 156, 190, 305, 390–1
PCOS (polycystic ovary syndrome) 127, 167, 234–5, 271, 355–60
INDEX

PCR (polymerase chain reaction) 293
peak height velocity (PHV) 85
peer groups 116
pelvic examination 175–9, 379
pelvic masses 254–9
see also ovarian cysts; ovarian tumors; PID (pelvic inflammatory disease); tumors/masses
pelvic/abdominal pain 260–8
acute 263–5, 344–7
chronic 260–3, 388
dysmenorrhea 325–9
ectopic pregnancy 256–7, 280, 339–41
endometriosis 351–4
ovarian cysts 342–3, 344–7
ovarian germ cell tumors 348–50
pelvic inflammatory disease 261, 263, 264
Penrose drains 65, 66
permethrin 323
pertussis vaccines 142
pharyngeal gonorrhea 308–9
physical activity 138–41, 328, 358
physical examination—see also genitourinary examination, gynecologic examination
acute pelvic/abdominal pain 264
ambiguous genitalia 9, 10
amenorrhea 272–3
candidal vulvovaginal infections 286
chlamydial infection 303–4
chronic pelvic/abdominal pain 262
developmental delay 159
endometriosis 352
gynecological examination 174–82
human papilloma virus 299
hymen 45
initial assessment 102
pelvic masses 256
prepubertal girls 4–5, 33
preventive care 120–3
puberty 85
sexual abuse in young children 40–1
sexual assault 372
sexually-transmitted infections 382
vulvar abscesses 64
vulvar lichen sclerosus 50, 69–70
PID (pelvic inflammatory disease) 361–5
acute pelvic/abdominal pain 263, 264
chronic pelvic/abdominal pain 261, 263
intrauterine devices 223
tubo-ovarian abscess 258
vaginal discharge 252
piercings, nipples 244
pilonidal sinus abscesses 67
pinworms 36
pituitary gland 80–1, 85, 91, 272
Plan B® 230, 232, 233
platelet function disorders 170
POI/POF (primary ovarian insufficiency/failure) 271
postpartum adolescents 229
Prader scale 9–10
precocious puberty 20–1, 87–90, 348
prefrontal cortex 116
pregnancy
see also contraception
adolescents, emancipation status 109
combined oral contraceptive failure 214
ectopic 256–7, 280, 339–41
HPV treatments safety 301
IUD in place at the time 225
minors’ consent laws 104
obese patients 127
screening for STIs 184
testing, pre-vaccination 143
Trichomonas vaginalis 314
unintended 187–91, 372, 373, 383–4
premenstrual dysphoric disorder (PMDD) 281–4
premenstrual syndrome (PMS) 281–4
prepubertal girls 1–53, 56–96
ambiguous genitalia 6–12
delayed puberty 91–6
female genital mutilation 76–9
hymen 45–8
initial assessment 3–5
labial adhesions 29–32
lichen sclerosus 50, 69–71
normal puberty 80–6
ovarian germ cell tumors 348
ovarian masses 22–8
precocious puberty 20–1, 87–90
sexual abuse 3, 4, 14, 16, 33, 38–42
trauma 72–5
vaginal bleeding 18–21
vaginal discharge/odor 14–17
vulvar signs/symptoms 49–71
vulvovaginal infections 376
vulvovaginitis 33–7
preventive care 119–24, 257, 309
primary amenorrhea 270
primary dysmenorrhea 325, 326, 327
privacy 101–2, 104
see also confidentiality
progestin
acute abnormal uterine bleeding 278
dysmenorrhea 327, 329
endometriosis 353
progestin-only contraception 215, 226–9
progestin-only implants 215, 228–9
progestin-only pills 215, 226
switching to from COCs 215, 386
prolactin 272
prozone effect 319
psoriasis, vulvar 51, 52
psychological effects 203, 296, 373–4, 387
INDEX

psychosocial causes 102, 261, 388

Pthirus pubis 322–3

pubarche 20–1, 87, 88, 89, 91

puberty 20–1, 53–6, 80–6, 87–90, 91–6

pubic lice 322–3

pulmonary embolism 101, 203, 220, 283

pure gonadal dysgenesis 271, 367, 368, 369

radiation therapy 272

rape 371–4

rash, vulvar 51–2, 54

rectal examination 262—see also genitourinary examination, gynecologic examination, physical examination

recurrent respiratory papillomatosis (RRP) 297

recurrent vulvovaginitis 37

referral reasons 175, 304–5, 378, 379

referred pain 266–8

renal anomalies 332, 337

reportable diseases 111

respiratory pathogens 15

Rotterdam Criteria 356

rudimentary uterine horn 334

safety of medications 144, 214, 220, 232

SAHM (Society for Adolescent Health and Medicine) 100, 228

SAMHSA (Substance Abuse and Mental Health Services Administration) 146

sample provision 17, 185

SBIRT framework 146, 147

screening

cervical cancer 174, 176, 180–2

eating disorders 135

gonorrhea/chlamydia 224

obese patients 128

preventive care 119–24

psychological 151–3, 387

sexually-transmitted diseases 183–6, 315, 316, 364

substance abuse 146–50

suicidal ideation/self-harm 151–3

sea sponges 164

sebaceous cysts, vulvar 52

secondary amenorrhea 270

secondary dysmenorrhea 325, 326

seizures 201–2

SELENA (Safety of Estrogen in Lupus: National Assessment) trial 200

self-harm 104, 111, 151–3

self-image, normal 86

septate hymen 45, 46

septate uterus 331, 332, 333

sexual abuse 104

assault/date rape 371–4

children, pubic lice 323

developmental delay 161, 162

normal external genital exam 47

prepubertal 3, 4, 14, 16, 33, 38–42

vulvar signs/symptoms 14, 16, 33, 52, 73

sexual activity 116, 117

bacterial vaginosis 289

confidential history-taking 382

HPV 297–301

LGBTQ healthcare 155–6

pelvic inflammatory disease 361, 362, 363, 364

young children 38, 40

sexual hair 20–1, 87, 88, 89, 91, 234–40

sexual maturity staging 82

sexuality 114–18, 154–7, 160–2

sexually-transmitted infections (STIs)

see also individual infectious organisms

adolescent sexuality 116

cervical cytology screening 180, 181, 182

condoms 205, 206

contraceptive counseling 194

genital herpes 293–4

history-taking 382

minors' consent laws 105–6

pelvic inflammatory disease 361, 362, 363, 364

physical examination 382

screening 102, 123, 183–6

sexual abuse in young children 41

sexual assault 372, 373

susceptibility increase 312, 313

vaginal discharge/odor, prepubertal girls 16

Shigella flexneri 36

sibutramine 129

sickle cell disease (SCD) 200

simple ovarian cysts 23, 24, 25

Skene's gland abscess 55, 67

skin conditions

lichen sclerosus 69–71

prepubertal vaginal bleeding 19

vulvar 51–2, 54, 55, 61, 64–5

social history 119–20, 121

social media 117

sonograms see ultrasound

SOX9 gene 366

spironolactone 239, 240

sponges, contraceptive 206, 207, 208

SSRIs (selective serotonin reuptake inhibitors) 283, 284

stages of adolescence 114, 115, 120, 192–4, 381

staging

ovarian germ cell tumors 349, 350

Tanner staging 82, 120, 123, 242, 381

Staphylococcus aureus 61, 164, 246

state-related legal aspects 105–6, 108–12

straddle injuries 72, 73

streptococcal vulvovaginitis 34, 51–2
Streptococcus pyogenes 36, 37, 61, 246
stress, LGBTQ healthcare 154–6
struma ovarii 27
substance abuse 146–50, 156
Sudan stain 247
suicidal ideation 151–3
surgery
  Bartholin’s gland abscess 65–7
  cervical LEEP loop electrosurgical excision procedures 181
  developmental delay 162
  ectopic pregnancy 339, 340, 341
  obese patients 128, 129–30
  ovarian cysts 344, 345, 346, 347
  ovarian germ cell tumors 349, 350
  prepubertal labial adhesions 31, 32
  vulvar abscesses 64, 65
Swyer syndrome 271, 367, 369
symmetric uterine anomalies 331
syphilis 184, 318–20
syringomas, vulvar 54, 55
systemic lupus erythematosus (SLE) 197, 200
tampons 47, 163, 164, 338
Tanner staging 82, 120, 123, 242, 381
teratomas 26–7, 348
terminology 9, 12, 30, 275, 276
testosterone 236, 237, 238, 270, 335
tetanus toxoid 142, 372
thalassemia 200
thelarche
  delayed puberty 92
  normal 80, 81, 82, 83
  premature 87, 88, 89, 90
therapeutic lifestyle change (TLC) 129
third party consent 108
thyroid tissue-containing teratomas 27
timing of normal puberty 81–2
Title X funding program 109, 110, 112
torsion
  ovarian 23, 255, 264, 338, 339, 343, 344, 389
  prepubertal 25, 28
toxic shock syndrome (TSS) 163–4, 206
transcutaneous nerve stimulation (TENS) 328
transdermal patches 215, 217–21, 386
transgender issues 154–7
transvaginal rings 215, 217–21, 386
transverse vaginal septum 257, 270, 336–7
trauma/injury 266
  see also sexual abuse
  accidental 19, 72–5
  date rape 371–4
  healing times 74
LGBTQ healthcare 156
Tetanus toxoid 142, 372
Treponema pallidum 318–20
tretinoin 322
Trichomonas vaginalis (TV) 16, 41, 249, 250, 251, 312–14
trimethoprim–sulfamethoxazole 321
tubal masses 255–6
tuberculosis screening 123
tubo-ovarian abscess (TOA) 256, 258, 364
tumors/masses
  see also malignancy
  abnormal uterine bleeding 20, 21, 276
  adnexal 389
  benign 242, 243, 343, 348
  breasts 242, 243
  markers 349
  ovarian 388
    cysts 23, 25, 89, 342–7, 355–60
    germ cell tumors 348–50
    precocious puberty 89
    prepubertal 22–8
    pelvic 254–9
    vulvar 60–3
Turner syndrome 92, 94, 271–2, 367–8
ulcers 57–9, 319, 320
ulipristal acetate 231, 232
ultrasound
  abnormal uterine bleeding 276
  acute pelvic/abdominal pain 264
  ambiguous genitalia 10
  breast masses 242, 244
  chronic pelvic/abdominal pain 262
  dysmenorrhea 326
  early thelarche 89
  ectopic pregnancy 340
  obese patients 127
  pelvic masses 254
  polycystic ovary syndrome 356, 357
  uterine anomalies 335
  see also imaging
unicornuate hemiuterus 331, 332
unilocular cysts 388
unintended pregnancy 187–91, 372, 373, 383–4
United States Medical Eligibility Criteria for Contraceptive Use 198, 200, 210, 211, 229, 232
urine tract
  acute pelvic pain 263, 264
  chronic pelvic pain 261, 262, 388
  female genital mutilation 78
  infections (UTIs) 206
  obstructions 30, 31, 32
  pelvic masses 256, 259
  prepubertal vaginal bleeding 19–20
uterine anomalies 330–6
    asymmetric 331–3
    cervical 333, 334
    congenital 333–6, 366–70
    Müllcrarian 270, 330–8, 366–70
    obstructive 256, 257–8, 337
    symmetric 331
    ultrasound 335
vaccinations 123, 142–5, 180, 182
vagina 249–53
    agenesis 333–6
    amenorrhea 270
    bacterial vaginosis 289–92
    candidal infections 36, 53–4, 249, 250, 251, 285–8
    chlamydial infection 302–6
    contraceptive methods 217–21
    flora, normal 15
    gonorrhea 307–11
    MRKH 270, 333–6
    mucosal barrier breakdown 312, 313
    normal prepubertal 35
    obstructed hemivagina, ipsilateral renal agenesis
    syndrome (OHV-IRA) 337
    prepubertal girls 14–17, 18–21, 50–1
    Trichomonas vaginalis 312–14
    uterovaginal agenesis 333–6
    vaginoscopy, straddle injuries 73
    vaginosits 249
    valacyclovir 295
    VCUAM (Vaginal–Cervical–Uterine–Adnexal-associated
    Malformation) system 330
venous thromboembolism (VTE) 101, 203, 220, 283
vestibular mucous cysts 62–3
victimization 154–6
violence 104, 111, 156, 371–4
virilization, degree of 9–10
vision tests 123
vitamin D 139, 354
vomiting
    childhood masses 24
    COCs 213
    developmental delay 160
    dysmenorrhea 326
    eating disorders 132, 134, 135, 140
    ectopic pregnancy 341
    emergency contraception 232
    Fallopian tube anomalies 338
    IUD insertion 224
    metronidazole 313
    pelvic pain 256, 257, 258, 261, 262, 264
    von Willebrand (VW) disease 167, 170
    VTE (venous VW disease) 101, 203, 220, 283
vulva
    abscesses 55, 64–8
    accidental trauma 72–5
aphthosis 57–9
delayed puberty 91–6
female genital mutilation 76–9
itching 50, 53–4
lichen sclerosus 69–71
lumps/bumps/lesions 52–3, 54–5
medical illness-associated conditions 376
normal flora 64
normal puberty 80–6
overview 49–56
precocious puberty 87–90
rash 51–2, 54
signs/symptoms 49–68
Tumors/cysts/masses 60–3
ulcers/aphthosis 57–9
vaginal discharge 50–1
vulvovaginal conditions 285–92, 378
    candidiasis (VVC) 36, 53–4, 249, 250, 251, 285–8
    prepubertal girls 376
vulvovaginitis
    see also candidal infections; HSV (herpes simplex
    virus)
bacterial vaginosis 249, 250, 251, 289–92
    Chlamydia 302–6
gonorrhea 224, 307–11
labial adhesions 29, 30
nonspecific 15
prepubertal 33–7, 376
trichomoniasis 16, 41, 249, 250, 251, 312–14
vaginal bleeding 18–19
warts 53, 297, 298, 299, 300, 301
    see also HPV (human papilloma virus)
vulvar condylomas 54, 55
web addresses 156, 190, 305, 390–1
weight 125–37, 226, 227
    BMI 85, 120, 124, 125, 126, 127
    wet prep 285, 286, 313
    Wnt-4 gene 330, 366
Word catheters 66, 67
World Health Organization (WHO) 76, 211
XX pure gonadal dysgenesis 367, 368
XY disorders 270–1, 367, 369
Y chromosome material 367
yeast infections
    candidal vulvovaginitis 36, 53–4, 249, 250, 251, 285–8
    vaginal discharge/odor 15–16
    vulvitis 53–4
Yersinia enterocolitica 36
young children 38, 39–41, 112, 298, 321–3, 377
    see also infants; neonates; prepubertal girls
Yuzpe regimen 231